神经内分泌肿瘤肝转移的动脉内治疗:倾向性评分分析比较传统TACE、药物洗脱微球TACE和钇-90放射栓塞
回顾性分析192例胃肠胰神经内分泌肿瘤肝转移患者,分别接受cTACE(N=122)、DEB-TACE(N=26)或Y90(N=44),中位总生存期分别为33.8、21.7和23.6个月,多变量分析显示cTACE较DEB-TACE(p<.01)和Y90(p=.02)显著延长总生存期,5年生存率分别为28.2%、10.3%和18.5%。
要点
- cTACE组中位总生存期33.8个月,长于DEB-TACE组21.7个月和Y90组23.6个月。
- 多变量分析显示cTACE较DEB-TACE(p<.01)和Y90(p=.02)显著延长总生存期。
- 年龄>70岁、肝外转移和肿瘤负荷>50%为负性预测因素。
核心结论
- 倾向性评分分析提示cTACE较DEB-TACE和Y90显著延长不可切除NELM患者的总生存期,支持将cTACE作为首选动脉内治疗选择直至被其他证据推翻。
研究设计与样本
- 回顾性分析纳入2000至2014年192例胃肠胰神经内分泌肿瘤肝转移患者,cTACE组N=122、DEB-TACE组N=26、Y90组N=44,平均年龄58.6岁,男性占56%;采用围手术期MR成像按RECIST和WHO标准评估影像学疗效,生存分析包括倾向性评分分析、中位总生存期、肝无进展生存期、Kaplan-Meier log-rank检验及单变量和多变量Cox比例风险模型。
诊断标准与关键数值
- 影像学疗效按RECIST和WHO标准采用围手术期MR成像评估;全研究中位总生存期28.8个月,cTACE组33.8个月、DEB-TACE组21.7个月、Y90组23.6个月;cTACE、DEB-TACE和Y90组5年生存率分别为28.2%、10.3%和18.5%。
临床应用与阅片要点
- 作者认为该数据支持将cTACE作为不可切除NELM患者首选的动脉内治疗选择直至被其他证据推翻;年龄>70岁、肝外转移和肿瘤负荷>50%为负性预测因素。
局限性
- 原文为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM).
METHODS: This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014. Radiologic response to therapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) and World Health Organization (WHO) criteria using periprocedural MR imaging. Survival analysis included propensity score analysis (PSA), median overall survival (MOS), hepatic progression-free survival, Kaplan-Meier using log-rank test and the uni- and multivariate Cox proportional hazards model (MVA).
RESULTS: MOS of the entire study population was 28.8 months. As for cTACE, DEB-TACE and Y90, MOS was 33.8 months, 21.7 months and 23.6 months, respectively. According to the MVA, cTACE demonstrated a significantly longer MOS as compared to DEB-TACE (p <.01) or Y90 (p = .02). The 5-year survival rate after initial cTACE, DEB-TACE and Y90 was 28.2%, 10.3% and 18.5%, respectively.
CONCLUSIONS: Upon PSA, our study suggests significant survival benefits for patients treated with cTACE as compared to DEB-TACE and Y90. This data supports the therapeutic decision for cTACE as the primary intra-arterial therapy option in patients with unresectable NELM until proven otherwise.
KEY POINTS: • cTACE achieved a significantly longer overall survival in patients with unresectable NELM. • Patients treated with cTACE showed a prolonged hepatic progression-free survival. • cTACE, DEB-TACE and Y90 radioembolisation demonstrated comparable safety and toxicity profiles. • Age >70 years, extrahepatic metastases and tumour burden >50% were identified as negative predictors. • Propensity score analysis suggests the superiority of cTACE over DEB-TACE and Y90.
引用
- Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017. PMID: 28677067. doi:10.1007/s00330-017-4856-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。